Dong-A Pharmaceutical: Acquisition of European COS of an Active Anticancer Ingredient, Seoul, South
Korea, Jan. 24 /PRNewswire/




As the 1st leading company, Dong-A Pharmaceutical Co., Ltd. (President Kim, Won-Bae) announced that Dong-
A Pharmaceutical has been granted a CEP (Certificate of Suitability of Monographs of the European
Pharmacopoeia) for Epirubicin Hydrochloride, which is an active anticancer ingredient approved by the
European directorate for the Quality of Medicines (EDQM).




The action mechanism helps Epirubicin HCL bind to DNA to inhibit the nucleic acid synthesis.




As the second-generation anticancer ingredient which improves the side effects of the first generation
anticancer ingredient, Doxorubicin, it is broadly used to treat various types of breast, stomach and lung
cancers.




Also, CEP (Certification of Suitability of Monographs of the European Pharmacopoeia) is a certificate that
certifies the compliance of a material with the requirements laid down in the relevant monograph of the
European Pharmacopoeia.




Dong-A Pharmaceutical Co., Ltd. expects enterance into the European market with this CEP of Epirubicin
HCL and also its total sale will be more than USD 30 million in global markets such as Latin America, India, and
Australia.




Contact : Seong-Yeol Lee

Assistant Manager

ETC Export Dept.

International Business Div.

Phone : +82 2 920 8368

HP : +82 19 493 5711

Fax : +82 2 924 2662

e-Mail : esy@donga.co.kr

Internet: www.donga.co.kr



Dong-A Pharmaceutical Co., Ltd. Seong-Yeol Lee, Assistant Manager, ETC Export Dept.,

International Business Div.

Phone: +82-2-920-8368, HP: +82-19-493-5711, Fax: +82-2-924-2662, esy@donga.co.kr